GlassScriptPhysician profile
Hisham Bismar
NPI 1154371078
$6,076.92
in general payments reported to CMS, 2019-2025
29 companies · $614 in 2025
The $614 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $963 · 2020: $1,074 · 2021: $921 · 2022: $841 · 2023: $1,035 · 2024: $628 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.58 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,524.74 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,250.50 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $677.87 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $612.24 | 2020-2025 | Acthar |
| Jazz Pharmaceuticals INC. | $244.34 | 2021-2025 | |
| Insmed, INC. | $232.64 | 2023-2025 | Arikayce, Brinsupri |
| Regeneron Healthcare Solutions, INC. | $222.24 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.49 | 2020-2025 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.03 | 2019-2022 | |
| Grifols USA, LLC | $105.85 | 2019-2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $82.75 | 2019 | |
| Boston Scientific Corporation | $82.67 | 2020-2022 | |
| Intuitive Surgical, INC. | $74.75 | 2019 | |
| Allergan, INC. | $54.70 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Electromed, INC. | $49.76 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $46.40 | 2021 | |
| Inspire Medical Systems, INC. | $46.34 | 2023-2024 | Inspire |
| Genentech USA, INC. | $40.81 | 2022-2023 | Xolair |
| Shire North American Group INC | $39.13 | 2019 | |
| Mallinckrodt Enterprises LLC | $37.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.27 | 2021-2025 | |
| Tactile Systems Technology INC | $25.03 | 2024 | Flexitouch Plus, Entre Plus |
| Merck Sharp & Dohme LLC | $24.52 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.53 | 2023 | Nuzyra |
| Vapotherm INC | $15.96 | 2021 | |
| Pfizer INC. | $15.50 | 2020 | |
| Optinose US, INC. | $13.67 | 2019 | |
| 3b Medical, INC. | $9.46 | 2023 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hisham Bismar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.